Filer Snapshot

Verve Therapeutics, Inc.

CIK 0001840574. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

344

Latest filing

14 Aug 2025

Industry

n/a

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: SEC filing timeline only. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Go to filings Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

—

No recent parsed 13D/G stake row for this CIK.

Browse 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Schedule 13D/G

SCHEDULE 13G filed on 14 Aug 2025 for CIK 0001840574.

View source filing
At a glance Names, identifiers, and filing context for this profile. 1 identity field
Business address
201 Brookline Avenue, Suite 601, Boston, MA, 02215
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 2 profile fields available
Incorporated in
DE
Fiscal year end
31 December

Filer intelligence

What SEC filings say about Verve Therapeutics, Inc.

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

SEC source mix

Counts show available parsed rows, not one combined ownership total.

No XML rows yet
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

13D/G stakes No rows yet

Beneficial ownership and large-stake disclosures.

Forms 3/4/5 No rows yet

Officer, director, and 10% owner holdings or transactions.

No parsed ownership summary yet

We still show the SEC filing timeline below. The intelligence summary will populate when parsed 13F, 13D/G, or Forms 3/4/5 data exists for this CIK.

SEC filing record

CIK 0001840574 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
344
First seen
22 Jan 2021
Latest filing
14 Aug 2025
Entity
Company

Observed form types

SCHEDULE 13G SCHEDULE 13G/A 15-12G EFFECT 4 POS AM 8-K POSASR S-8 POS 25-NSE +32 more

CIK-linked evidence first

Verve Therapeutics, Inc. SEC filings Open SEC filing index

Latest Filings

Showing the latest 12 of 344 SEC filings for Verve Therapeutics, Inc..

Open full filing history
SCHEDULE 13G File 005-92605

SCHEDULE 13G filing

Filing date
14 Aug 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A File 005-92605

SCHEDULE 13G/A filing

Filing date
14 Aug 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
15-12G File 001-40489

15-12G

Filing date
04 Aug 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-267578

EFFECT filing

Filing date
28 Jul 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A File 005-92605

SCHEDULE 13G/A filing

Filing date
28 Jul 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
28 Jul 2025
Reporting date
25 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
28 Jul 2025
Reporting date
25 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
28 Jul 2025
Reporting date
25 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
28 Jul 2025
Reporting date
25 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
28 Jul 2025
Reporting date
25 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
28 Jul 2025
Reporting date
25 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
28 Jul 2025
Reporting date
25 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .